테라젠이텍스
Financials
Valuation Metrics
테라젠이텍스's Market Cap is ₩788B. At end of 2025 it was ₩1174B. Ranked #1439 of 2,421 in KR market (top 59%), #826 of 1,640 on KOSDAQ (top 50%), #154 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 67%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 78.76B KRW | KR#1,439/2,421 Sec#154/231 |
| Revenue | 275.36B KRW | KR#873/2,421 Sec#42/231 |
| Net Income | 2.83B KRW | KR#1,358/2,421 Sec#95/231 |
| Total Assets | 241.17B KRW | KR#1,166/2,421 Sec#81/231 |
| Net Assets | 143.98B KRW | KR#1,167/2,421 Sec#84/231 |
| Employees | 214 | KR#1,048/2,421 Sec#86/231 |
| Value | ||
| P/E | 27.87x | KR#1,288/2,421 Sec#79/231 |
| P/B | 0.55x | KR#882/2,421 Sec#45/231 |
| P/S | 0.29x | KR#565/2,421 Sec#13/231 |
| EV/EBITDA | 11.13x | KR#674/2,421 Sec#34/231 |
| FCF Yield | 10.66% | KR#584/2,421 Sec#21/231 |
| Profitability | ||
| ROE | 1.96% | KR#1,413/2,421 Sec#97/231 |
| ROA | 1.17% | KR#1,379/2,421 Sec#99/231 |
| Op. Margin | 3.91% | KR#1,104/2,421 Sec#79/231 |
| Revenue Growth | 6.13% | KR#1,127/2,421 Sec#110/231 |
| Financial Health | ||
| Debt Ratio | 67.50% | KR#1,190/2,421 Sec#143/231 |
| Total Debt | 80.74B KRW | KR#798/2,421 Sec#49/231 |
| FCF | 8.40B KRW | KR#761/2,421 Sec#42/231 |
| Cash | 39.52B KRW | KR#862/2,421 Sec#54/231 |
| Current Ratio | 1.78x | KR#986/2,421 Sec#109/231 |
| Net Debt/EBITDA | 3.82x | KR#952/2,421 Sec#72/231 |
| Dividend | ||
| Div. Yield | 0.37% | KR#1,302/2,421 Sec#82/231 |
| Performance | ||
| 1Y Return | -26.77% | KR#1,464/2,421 Sec#111/231 |
| 1M Return | 2.91% | KR#937/2,421 Sec#67/231 |
| From 52W High | -38.90% | KR#879/2,421 Sec#61/231 |
| 1Y MDD | -43.05% | KR#693/2,421 Sec#52/231 |
| Trading | ||
| Volume | 37,647 shares | KR#1,267/2,421 Sec#127/231 |
| Trading Value | 79.7M KRW | KR#1,656/2,421 Sec#166/231 |
| Foreign Own. | 2.27% | KR#1,538/2,421 Sec#145/231 |
| Per Share | ||
| EPS | 76 KRW | KR#1,464/2,421 Sec#101/231 |
| BPS | 3,875 KRW | KR#1,693/2,421 Sec#124/231 |
Company Info
Theragen Etex, established in 1990 and listed on KOSDAQ in 2004, adopted its current name after merging with Etex Pharmaceutical in 2010. The company primarily manufactures and sells specialized and general medicines and provides genome sequencing services, with Leadfarm, Theragen Healthcare, and Theragen Bio as subsidiaries. Theragen Etex focuses on new drug R&D, DNA sequencing, and RNA variant genome analysis to address future medical changes, and is pursuing global market expansion through its Chinese local subsidiary. It is headquartered in Ansan-si, Gyeonggi-do.